Global rare disease policy shifts are reshaping orphan drug development, with major implications for equitable access in the UK, EU and US.
From April 2026, NICE raises its cost-effectiveness threshold to £25k–£35k per QALY. What it means for NHS funding, patients, ...
The OHE Annual Lecture is our opportunity to highlight urgent and important issues facing health systems around the world. OHE’s educational mission is to support, sustain, and enhance the discipline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results